7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
DIabetes REsearCh on patient sTratification (DIRECT)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,
The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet
27
Participants partenaires
TERMINÉ
Vaccination In Atherosclerosis (VIA)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,
"Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underl ...
Voir le projet
12
Participants partenaires
TERMINÉ
Targeting and exploiting B cell functions for treatment in cardiovascular disease (Athero-B-Cell)
Date du début: 1 sept. 2013, Date de fin: 31 août 2018,
Cardiovascular disease (CVD) mortality and morbidity is predicted to increase in Europe and worldwide in the next decades due to aging and the rise of diabetes and obesity. The link between metabolic and inflammatory disease is getting stronger, raising hopes for novel therapeutic targets to be exploited clinically. Clinical evidence generated by the Academic partners of the Athero-B-Cell Consorti ...
Voir le projet
11
Participants partenaires
TERMINÉ
General and targeted approaches to unravel the molecular causes of type 2 diabetes (GENE TARGET T2D)
Date du début: 1 mai 2011, Date de fin: 30 avr. 2016,
"Type 2 diabetes (T2D) affects worldwide at present about 250 million patients and an estimated 380 million in 2025. This epidemic has been ascribed to a collision between genes and an affluent society. Genetics of T2D has during recent years identified > 30 variants increasing susceptibility to T2D. Yet, these variants explain only 15% of the heritability of T2D. One reason could be that whole ge ...
Voir le projet
1
Participant partenaire
TERMINÉ
MOSAIC - MOdels and Simulation techniques for discovering diAbetes Influence faCtors (MOSAIC)
Date du début: 1 janv. 2013, Date de fin: 30 avr. 2016,
MOSAIC will address two very specific aspects linked to the prediction of risk of developing diabetes (type 2 and gestational) and complications associated to diabetes. These objectives respond to a widely recognized problem related to diabetes management and have the potential to have a major impact in the way diabetes is currently diagnosed and followed in Europe.\nThe MOSAIC consortium counts w ...
Voir le projet
11
Participants partenaires
TERMINÉ
SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT)
Date du début: 1 nov. 2009, Date de fin: 31 oct. 2015,
Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as we ...
Voir le projet
27
Participants partenaires
TERMINÉ
Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes (BetaBat)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,
A reduction in functional pancreatic beta cell mass is the key feature of type 1 and type 2 diabetes. Beta cell failure is exacerbated in the context of obesity and insulin resistance. Brown adipose tissue (BAT) is a highly metabolic organ, mediating energy dissipation and glucose disposal, thus contributing to maintain energy balance. BAT dysfunction contributes to obesity and impaired glucose me ...
Voir le projet